Esperion Therapeutics | ESPR - Betriebsaufwand

Aktienkurs
2.17
Täglich Wechseln
-0.01 -0.46%
Monatlich
-16.22%
Jährlich
112.75%
Q2 Prognose
2.11




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Cipla INR 60.98B 1.06B 2025-12
CSL USD 5.7B 2.82B 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Geron USD 58.8M 2.31M 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09